L2M – LigandQI: Empowering Drug Design with Quantum Information

Nearly 90% of drug candidates fail during the drug design and development process, resulting in exorbitant costs to bring a new drug to market. Our technology, LigandQI, addresses the critical shortcomings in current computational drug design programs by leveraging ab initio quantum chemistry to quantify ligand-receptor interactions with unprecedented accuracy. Unlike traditional methods, our program provides a comprehensive understanding of ligand-protein interactions at quantum information level, accelerating the drug discovery process. This innovative approach is designed to meet the evolving needs of researchers and pharmaceutical professionals, promising to drive innovation and expedite the development of targeted therapeutics.

Faculty Supervisor:

Stijn De Baerdemacker

Student:

Partner:

Springboard Atlantic Inc.

Discipline:

Life Sciences

Sector:

Quantum Science; Pharmaceuticals; Life Sciences (not health)

University:

University of New Brunswick

Program: